 |
|
GM-1 Treatment of Alzheimer's DiseaseA Pilot Study of Safety and Efficacy
Thomas Ala, MD;
Silvia Romero, MD;
Floyd Knight, MD;
Karen Feldt, RN, MSN;
William H. Frey II, PhD
Arch Neurol. 1990;47(10):1126-1130.
Abstract
• A double-blind, placebo-controlled pilot study was conducted to evaluate the safety and efficacy of treatment of patients with Alzheimer's disease using monosialoganglioside GM-1, a neurotrophic factor. Of 46 patients enrolled, 42 completed all study requirements. Nineteen patients received 100 mg of GM-1 by daily intramuscular injection for 12 weeks. Twenty-three patients received placebo. Case evaluations were done at baseline, week 12, and week 24 and included both cognitive and psychosocial scales. Study results suggested that the treatment was safe, yet offered no overall symptomatic benefit to patients with mild-to-moderate Alzheimer's disease. Whether or not GM-1 therapy may offer protective benefit by slowing or arresting the progression of the disease remains unclear, since the results of the cognitive evaluations suggested that neither the GM-1 group nor the placebo group declined significantly during the 24-week study.
Author Affiliations
From the Alzheimer's Treatment and Research Center, Ramsey Clinic/St Paul-Ramsey Medical Center, and University of Minnesota, St Paul.
Footnotes
Accepted for publication March 26, 1990.
Reprint requests to 640 Jackson St, St Paul, MN 55101 (Dr Ala).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Engagement of endogenous ganglioside GM1a induces tyrosine phosphorylation involved in neuron-like differentiation of PC12 cells
Kimura et al.
Glycobiology 2001;11:335-343.
ABSTRACT
| FULL TEXT
Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review
Patel
J Geriatr Psychiatry Neurol 1995;8:81-95.
ABSTRACT
|
